Elite Pharmaceuticals ELTP
OTC ELTP
$0.37 +0.05 (+15.63%)
At close: Nov 16, 2026 · 4:00 PM EST

Elite Pharmaceuticals (ELTP) Return on Sales [ROS] (2009 - 2026)

Updated

Elite Pharmaceuticals (ELTP) posted Return on Sales [ROS] of 24.76% for fiscal Q2 2027 (quarter ended Sep 30, 2026), up 2.15 percentage points from 22.61% a year earlier and up 1.49 percentage points from the prior quarter.

Analysis

Elite Pharmaceuticals (ELTP) Return on Sales [ROS] (2009 - 2026) Analysis & Trends

For the trailing twelve months through Sep 30, 2026, Return on Sales [ROS] at Elite Pharmaceuticals was 25.32%, down 8.99 percentage points year-over-year; for FY2026 (ended Mar 31, 2026), it came in at 32.99%, up 9.67 percentage points from FY2025.

  • Annual Return on Sales [ROS] has increased for three consecutive fiscal years, with a five-year change of +24.70 percentage points (FY2021 to FY2026).
  • In prior fiscal years, Elite Pharmaceuticals' Return on Sales [ROS] was 23.32% in FY2025 (+4.27 pp), 19.05% in FY2024 (+8.29 pp), 10.76% in FY2023 (-4.95 pp) and 15.72% in FY2022 (+7.43 pp).
  • Quarterly Return on Sales [ROS] has run from a low of -4.48% in fiscal Q4 2023 to a high of 53.96% in fiscal Q1 2026 over five years.
  • On a year-over-year basis, Return on Sales [ROS] increased in five of the last eight quarters, with an average year-over-year change of +2.38 percentage points.
  • The strongest year-over-year quarter for Return on Sales [ROS] in the past five years was fiscal Q4 2022, with a gain of 35.39 percentage points; the weakest was fiscal Q1 2027, with a drop of 30.69 percentage points.
  • According to Business Quant data, Return on Sales [ROS] for the three prior fiscal quarters was 23.27% (Q1 2027), 25.00% (Q4 2026) and 28.53% (Q3 2026).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn 24.35%
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn 36.01%
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn 30.74%
5 Novartis Ag 310.90 Bn 284.14 Bn - -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn 29.12%
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn 35.79%
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn 41.71%
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn 32.98%
10 Elite Pharmaceuticals 401.23 Mn 274.64 Mn 15.99 Mn 24.76%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 24.76%
Jun 30, 2026 23.27%
Mar 31, 2026 25.00%
Dec 31, 2025 28.53%
Sep 30, 2025 22.61%
Jun 30, 2025 53.96%
Mar 31, 2025 34.86%
Dec 31, 2024 7.64%
Sep 30, 2024 18.46%
Jun 30, 2024 20.55%
Mar 31, 2024 20.77%
Dec 31, 2023 22.73%
Sep 30, 2023 13.60%
Jun 30, 2023 17.84%
Mar 31, 2023 -4.48%
Dec 31, 2022 21.18%
Sep 30, 2022 12.59%
Jun 30, 2022 13.33%
Mar 31, 2022 11.10%
Dec 31, 2021 20.40%
API Access

Elite Pharmaceuticals Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=ELTP&period=max&api_key=YOUR_API_KEY